KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Share-based Compensation (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Share-based Compensation for 17 consecutive years, with $113.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 1.8% to $113.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $664.0 million through Dec 2025, down 1.34% year-over-year, with the annual reading at $664.0 million for FY2025, 1.34% down from the prior year.
  • Share-based Compensation hit $113.0 million in Q4 2025 for Abbott Laboratories, down from $120.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $305.0 million in Q1 2022 to a low of $106.0 million in Q4 2021.
  • Historically, Share-based Compensation has averaged $165.3 million across 5 years, with a median of $127.5 million in 2021.
  • Biggest five-year swings in Share-based Compensation: rose 23.61% in 2021 and later dropped 7.87% in 2023.
  • Year by year, Share-based Compensation stood at $106.0 million in 2021, then increased by 8.49% to $115.0 million in 2022, then decreased by 0.87% to $114.0 million in 2023, then fell by 2.63% to $111.0 million in 2024, then increased by 1.8% to $113.0 million in 2025.
  • Business Quant data shows Share-based Compensation for ABT at $113.0 million in Q4 2025, $120.0 million in Q3 2025, and $142.0 million in Q2 2025.